SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
NC Kyriakidis, A López-Cortés, EV González… - npj Vaccines, 2021 - nature.com
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and
causes COVID-19 disease. The newly sequenced virus appears to originate in China and …
causes COVID-19 disease. The newly sequenced virus appears to originate in China and …
The dawn of mRNA vaccines: The COVID-19 case
R Verbeke, I Lentacker, SC De Smedt… - Journal of Controlled …, 2021 - Elsevier
In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Neutralizing activity of BNT162b2-elicited serum
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from
persons injected with the BNT162b2 vaccine neutralize the P. 1, B. 1.1. 7, and B. 1.135 …
persons injected with the BNT162b2 vaccine neutralize the P. 1, B. 1.1. 7, and B. 1.135 …
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
viruses containing key spike mutations from the newly emerged United Kingdom (UK) and …
viruses containing key spike mutations from the newly emerged United Kingdom (UK) and …
Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera
A Muik, AK Wallisch, B Sänger, KA Swanson, J Mühl… - Science, 2021 - science.org
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage
called B. 1.1. 7 (variant of concern: VOC 202012/01), which is reported to spread more …
called B. 1.1. 7 (variant of concern: VOC 202012/01), which is reported to spread more …
SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
Over the past year, numerous studies in the peer reviewed and preprint literature have
reported on the virological, epidemiological and clinical characteristics of the coronavirus …
reported on the virological, epidemiological and clinical characteristics of the coronavirus …
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …
central to long-term control of the current pandemic. Despite our rapidly advancing …
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
The rapid implementation of SARS-CoV-2 vaccination is now a global health-care priority.
Successful phase 3 trial outcomes have been reported for numerous vaccines that induce …
Successful phase 3 trial outcomes have been reported for numerous vaccines that induce …
Self-assembled mRNA vaccines
Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …